SecBot SecBot

IDXG

INTERPACE BIOSCIENCES, INC.
OTC· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001054102 Biotech & Drug Discovery
$5.50 −1.00 (−15.38%)
Oct 26 4:00 PM ET · prev $6.50
Market cap
$21.9M
Nano cap
Next earnings
Nov 10
in 15 days
1 year
+400.0%
from $1.10 · Oct 27
30 days
−14.3%
from $6.42
52-week range
$0.8300–7.62
−28% from high · low Nov 24
Avg volume 20D
1.6K
Oct 19 spike 7.1K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M-$10.4M, representing ~15-18% YoY…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • TrendRANGE

    2% above its 50-day average.

The Street

last action Nov 2021
Recent actions
DateFirmActionRating
Nov 17, 2021HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Apr 9, 2021HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jan 25, 2021HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 22, 2020HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 26, 2020HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Apr 23, 2020HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
IDXG Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Aug 5, 2026
Earnings date
IDXG Q2 2026 Earnings Scheduled — 2026-08-05
May 6, 2026
Earnings date
IDXG Q1 2026 Earnings Scheduled — 2026-05-06
Mar 30, 2026
Earnings date
IDXG Q4 2025 Earnings Scheduled — 2026-03-30

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 20, 2026
McCarthy Christopher
CFO & COO
AWARD554,018 sh
Aug 20, 2026
SULLIVAN STEPHEN J
Director
AWARD69,252 sh
Aug 20, 2026
McCarthy Christopher
CFO & COO
EXERCISE277,009 sh
Aug 20, 2026
McCarthy Christopher
CFO & COO
AWARD277,009 sh
Aug 20, 2026
Rocca Fortunato R.
Director
AWARD69,252 sh
Aug 20, 2026
KEEGAN JOSEPH D
Director
AWARD69,252 sh
Aug 20, 2026
AGGARWAL VIJAY
Director
AWARD69,252 sh
Aug 20, 2026
Burnell Thomas W.
CEO, President & Chairman
EXERCISE1,966,763 sh

Earnings setup

Estimates
Nov 10
reports in 15 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M-$10.4M, representing ~15-18% YoY growth and…
8-K — Impact 5/10
Sep 30, 2026 SEC
Interpace Biosciences is filing Amendment No. 1 to its S-1 registration statement for a firm-commitment IPO of…
S-1/A — Impact 5/10
Aug 20, 2026 Insider
McCarthy Christopher was granted 554,018 shares
CFO & COO
Aug 20, 2026 Insider
SULLIVAN STEPHEN J was granted 69,252 shares
Director
Aug 20, 2026 Insider
McCarthy Christopher acquired via exercise 277,009 shares
CFO & COO
Aug 5, 2026 Earnings calendar
IDXG Q2 2026 Earnings Scheduled — 2026-08-05
Apr 1, 2026 SEC
Interpace Biosciences reported full-year 2025 revenue of $38.7 million and income from continuing operations of $25.0…
8-K — Impact 6/10

SecBot reports

3 filings · 1 bullish · 0 bearish · 1 mixed · 1 neutral
All IDXG filing & press-release reports (3)